Healthcare / BiotechnologyNasdaqCM
$2.20
-0.03 (-1.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-29.6M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
6/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$41M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-385.6%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2015–2025 · 10 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.19x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-27.0M · FCF $-32.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | — | — | — | — | $3.9M | — | — | — | — | $0.00 | $0.00 | $45000.00 |
| Net Income | $-27.0M | $-27.0M | $-38.5M | $-42.2M | $-44.8M | $-142.6M | $-104.3M | $-94.3M | $-66.7M | $-42.2M | $-33.2M | $-16.7M |
| EBITDA | $-23.4M | $-23.4M | $-32.5M | $-36.1M | $-37.0M | $-129.3M | $-95.3M | $-87.4M | — | — | — | — |
| EPS | -165.50 | -165.50 | -507.50 | -867.50 | -1474.00 | -5416.00 | -4975.00 | — | — | — | — | — |
| Gross Margin | — | — | — | — | 34.2% | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | -2090.3% | — | — | — | — | — | — | -35435.6% |
| Net Margin | — | — | — | — | -1151.6% | — | — | — | — | — | — | -37071.1% |
| Balance Sheet | ||||||||||||
| Debt/Equity | — | — | 2.62 | 4.84 | 2.26 | 4.70 | 0.72 | 2.40 | 0.67 | 0.13 | -0.10 | — |
| Current Ratio | 7.91 | 7.91 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $-32.0M | $-32.0M | $-29.6M | $-28.5M | $-79.2M | — | — | $-94.1M | $-55.7M | $-34.6M | $-27.5M | $-15.3M |
| Returns | ||||||||||||
| ROE | -385.6% | -385.6% | -312.3% | -562.4% | -236.2% | -848.6% | -104.3% | -317.8% | -63.6% | -47.1% | 37.8% | 29.4% |
| Valuation | ||||||||||||
| P/B | 0.05 | 0.05 | 2.44 | 2.27 | 2.36 | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | — | — | -100.0% | — |
| EPS Growth | 67.4% | 67.4% | 41.5% | 41.1% | — | -8.9% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-98.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-507.50 → -165.50
Residual
-98.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.